Suppr超能文献

血小板激活因子:在缺血/再灌注心脏中的好与坏。

Platelet activating factor: the good and the bad in the ischemic/reperfused heart.

机构信息

Dipartimento di Scienze Cliniche e Biologiche, ASO San Luigi, 10043 Orbassano (TO), Italy.

出版信息

Exp Biol Med (Maywood). 2011 Apr 1;236(4):390-401. doi: 10.1258/ebm.2011.010316. Epub 2011 Mar 4.

Abstract

The present review is focused on the dual role played by platelet-activating factor (PAF) in ischemia and reperfusion (I/R) injury of the heart. Although the involvement of PAF in the pathogenesis of myocardial reperfusion injury is well established, in the last few years it has emerged that very low concentrations of PAF exert cardioprotective effects, comparable to that afforded by ischemic preconditioning (IP). PAF is a potent phosphoglyceride involved in different pathophysiological conditions affecting the cardiovascular system, including the development of myocardial I/R injury. PAF is released from the I/R myocardium in concentrations (1-10 nmol/L) high enough to negatively modulate coronary circulation as well as electrical and contractile activities. PAF may act either directly, via generation of secondary mediators, or through the activation of inflammatory cells like platelets and polymorphonuclear neutrophils, which exacerbate postischemic myocardial injury. The effects of PAF are mediated through specific receptors (PAFRs) that belong to the superfamily of G protein-coupled receptors. Since cardiomyocytes not only produce PAF but also possess PAFRs, it is likely that PAF acts as an autocrine/paracrine mediator. Although the negative effects exerted by high concentrations of PAF are well established, several recent findings from our and other laboratories have demonstrated that very low concentrations (pmol/L) of PAF infused before ischemia induce cardioprotective effects similar to those afforded by IP, and that endogenous PAF production participates in the induction of IP itself. The IP-like action exerted by low concentrations of PAF is due to the activation/phosphorylation of kinases included in the reperfusion injury salvage kinase (RISK) pathway, such as protein kinase C, Akt/PkB and nitric oxide synthase. Together with the activation of mitochondrial K(ATP) channels, these events may allow prevention of mitochondrial permeability transition pores opening at reperfusion. Moreover, the nitric oxide-dependent S-nitrosylation of L-type Ca(2+) channels induced by PAF reduces intracellular Ca(2+) overload.

摘要

本文重点讨论血小板激活因子(PAF)在缺血再灌注(I/R)损伤中的双重作用。虽然 PAF 参与心肌再灌注损伤的发病机制已得到充分证实,但近年来发现,极低浓度的 PAF 可产生与缺血预处理(IP)相当的心脏保护作用。PAF 是一种参与影响心血管系统的不同病理生理条件的强效磷酸甘油酯,包括心肌 I/R 损伤的发展。PAF 从再灌注心肌中释放出来,其浓度(1-10nmol/L)足以负性调节冠状动脉循环以及电和收缩活性。PAF 可能通过产生二级介质直接作用,或通过激活血小板和多形核白细胞等炎症细胞来发挥作用,从而加重缺血后心肌损伤。PAF 的作用是通过属于 G 蛋白偶联受体超家族的特定受体(PAFRs)介导的。由于心肌细胞不仅产生 PAF,还具有 PAFRs,因此 PAF 可能作为自分泌/旁分泌介质发挥作用。虽然高浓度 PAF 产生的负面影响已得到充分证实,但我们和其他实验室的最近几项发现表明,在缺血前输注极低浓度(pmol/L)的 PAF 可诱导类似于 IP 的心脏保护作用,并且内源性 PAF 产生参与 IP 的诱导本身。低浓度 PAF 发挥的 IP 样作用归因于再灌注损伤挽救激酶(RISK)途径中包括蛋白激酶 C、Akt/PkB 和一氧化氮合酶在内的激酶的激活/磷酸化。与线粒体 KATP 通道的激活一起,这些事件可能允许在再灌注时防止线粒体通透性转换孔打开。此外,PAF 诱导的一氧化氮依赖性 L 型 Ca2+通道 S-亚硝基化可减少细胞内 Ca2+超载。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验